| 词条 | Relacorilant |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = [(4aR)-1-(4-Fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone | image = Relacorilant.svg | width = | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = By mouth | class = Antiglucocorticoid | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 1496510-51-0 | CAS_supplemental = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = 73051463 | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 57617720 | UNII = 2158753C7E | KEGG = D11336 | ChEBI = | ChEMBL = | synonyms = CORT-125134 | C=27 | H=22 | F=4 | N=6 | O=3 | S=1 | molecular_weight = 586.566 g/mol | SMILES = CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F | StdInChI_Ref = | StdInChI = 1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = WANIDIGFXJFFEL-SANMLTNESA-N }}Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome.[1] It is also under development for the treatment of solid tumors and alcoholism.[1][2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.[1] See also
References1. ^1 2 3 http://adisinsight.springer.com/drugs/800041622 2. ^{{cite journal | vauthors = Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF | title = High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer | journal = Gynecol. Oncol. | volume = 146 | issue = 1 | pages = 153–160 | year = 2017 | pmid = 28456378 | doi = 10.1016/j.ygyno.2017.04.012 | url = }} External links
9 : Antiglucocorticoids|Experimental drugs|Fluoroarenes|Isoquinolines|Ketones|Pyrazoles|Pyridines|Sulfones|Trifluoromethyl compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。